FDA noted that the lack of a suitable potency assay for the RYONCIL product used during the
Phase 3 trial MSB-GVHD001 for the pediatric acute GVHD indication has prevented the trial from
being considered an adequate study for the purpose of demonstrating substantial evidence of
effectiveness required for a marketing approval.
ddwn, nothing will happen till the above is complete and this will take a few months. This includes ARDS and will have some sort of impact with others. Perception!
banter and General Discussion, page-7661
-
- There are more pages in this discussion • 2,491 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.324B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $5.464M | 4.646M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 55 | 85386 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 85323 | 12 |
View Market Depth
| Last trade - 15.37pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |